Chinese
Japan
English
500+ Antibody Humanization Projects
Guarantee no loss of affinity
The most advanced project is marketed
By Jan. 2024
Antibody humanization & antibody characterization can reduce the immunogenicity of monoclonal antibodies derived from xenogeneic sources and improve their activation of the human immune system by replacing non-human antibody frameworks with human ones. It is a very important step in the therapeutic antibody discovery process. ProBio is the world’s No.1 fast antibody humanization service provider, providing 2 packages for antibody humanization services.
Through CDR grafting and back mutation technologies, the express package can be used to produce humanized antibodies with high expression levels, good thermal stability, and comparable affinity with the parental antibodies as fast as 2.5 weeks.
Deluxe package can be used to obtain the humanized antibodies without affinity loss through CDR grafting, back mutation, and FASEBA high-throughput screening technology as fast as 8 weeks.
FASEBA is a patented E.Coli based system that selects good affinity, expression level and thermostable candidates. It is used to select the best protein binders from a large number of protein candidates in a high throughput fashion, without actually purifying these proteins
Each saturation mutation library is transformed into FASEBA E.coli based expression system
Immunogenicity can potentially lead to reduced efficacy through rapid clearance or neutralization of the drug, or toxicity due to cross-reaction with proteins in the body, which can have catastrophic consequences for the patient. Antibody humanization & antibodies characterization can reduce the immunogenicity of monoclonal antibodies derived from xenogeneic sources and to improve their activation of the human immune system by replacing non-human antibody frameworks with human ones. It is a very important step in therapeutic antibody discovery process.
A common method for humanization of non-human antibodies is complementary determining regions (CDR) grafting in which the CDRs of non-human antibodies are grafted onto the human frameworks. But only CDR grafting is not enough to get eliminate the risk of immunogenicity very well. Usually, back mutation will be performed to further transfer CDRs into human frameworks as similar as possible. In this step PTM hot spot analysis can be applied to increase the probability to get humanized antibody with least affinity loss and normal function.
Also, FASEBA(Fast Screening for Expression, Biophysical-properties and Affinity) high throughput screening can be applied to screen out humanized antibody with best affinity.
ProBio provides 2 packages for antibody humanization service. Deluxe package using CDR-grafting, back mutation with PTM analysis and screening with FASEBA which can guarantee no affinity loss for the humanized antibody. Express package using CDR grafting and back mutation to generate humanized antibody as fast as 3 weeks.
Patented FASEBA screening platform
Antibody Humanization
We offer 3 developability assessment packages for antibody drug candidates at different discovery stages to identify the potential risks of manufacture and clinical failure.
The turnaround time listed here is the time required for the service itself. For international shipping, please refer to the time provided by PM during project discussion.
Table.1 Affinity kinetic analysis
Fig.1 Affinity kinetic analysis of humanized antibody
ELISA test was performed to evaluate binding between humanized and chimeric antibodies, and the same binding profile was observed based on the ELISA results.
Fig.2 Comparison of the affinity of humanized antibodies to parental antibody
FACS test was performed to evaluate binding between humanized and chimeric antibodies, and the same binding profile was observed based on the FACS results.
Fig.3 Comparison of the affinity of humanized antibodies to parental antibody
“We are pleased with the antibody humanization service and the purification service of ProBio. It is very impressive and professional. we validated the humanization service by testing the antibody against anti-human IgG as the secondary antibody. The humanized antibody purification met our expectations and need. The characterization of the antibody that was highlighted by the COA is excellent. We would continue to avail your service and will also recommend it to anyone who needs such service. Thanks.” – Govind Panchamoorthy, Director, Genus Oncology
Please download service quotation form and fill it before sending to us.